Zacks Investment Research Downgrades Vascular Biogenics Ltd. (VBLT) to Sell
Vascular Biogenics Ltd. (NASDAQ:VBLT) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Wednesday.
According to Zacks, “Vascular Biogenics Ltd. is a clinical stage biotechnology company. It is focused on the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its lead oncology candidate VB-111, is a gene-based biologic which is in Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer. It is also developing VB-201, an oral small molecule that is in Phase II clinical trials for the treatment psoriasis and ulcerative colitis. Vascular Biogenics Ltd. is headquartered in Or Yehuda, Israel. “
Several other equities research analysts have also issued reports on VBLT. HC Wainwright began coverage on shares of Vascular Biogenics in a report on Tuesday, June 28th. They issued a “buy” rating and a $11.00 target price for the company. Roth Capital restated a “buy” rating and issued a $17.00 target price on shares of Vascular Biogenics in a report on Tuesday, August 16th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $13.67.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/19/zacks-investment-research-downgrades-vascular-biogenics-ltd-vblt-to-sell.html
Shares of Vascular Biogenics (NASDAQ:VBLT) opened at 5.00 on Wednesday. Vascular Biogenics has a one year low of $2.76 and a one year high of $8.18. The stock’s market cap is $118.01 million. The firm has a 50-day moving average of $4.77 and a 200-day moving average of $4.09.
Vascular Biogenics (NASDAQ:VBLT) last released its earnings results on Monday, August 15th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.09. On average, equities research analysts expect that Vascular Biogenics will post ($0.64) earnings per share for the current fiscal year.
Large investors have recently made changes to their positions in the stock. Macquarie Group Ltd. bought a new stake in shares of Vascular Biogenics during the second quarter worth $1,521,000. Menta Capital LLC raised its stake in Vascular Biogenics by 4.1% in the second quarter. Menta Capital LLC now owns 33,200 shares of the biopharmaceutical company’s stock valued at $153,000 after buying an additional 1,300 shares in the last quarter. Franklin Resources Inc. acquired a new stake in Vascular Biogenics during the second quarter valued at approximately $4,191,000. First Eagle Investment Management LLC raised its stake in Vascular Biogenics by 371.1% in the second quarter. First Eagle Investment Management LLC now owns 923,239 shares of the biopharmaceutical company’s stock valued at $4,256,000 after buying an additional 727,273 shares in the last quarter. Finally, Turner Investments L.P. acquired a new stake in Vascular Biogenics during the second quarter valued at approximately $1,007,000. Institutional investors own 14.46% of the company’s stock.
About Vascular Biogenics
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vascular Biogenics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.